[signal.]portfolio & asset diligence

Org: Demo Translational Institute — structured asset diligence, not investment advice.

← Portfolio

Microdystrophin Gene Transfer (DMD)

Edit / manage →

Duchenne muscular dystrophy

Phase 2Clinical entryGene therapy (AAV)NeuromuscularMixed· medium conf3 evidence-linked claims2 snapshots

Overview

Disease area
Neuromuscular
Indication
Duchenne muscular dystrophyMONDO:0010679
Mechanism of action
Systemic AAV delivery of microdystrophin transgene
Development stage
Phase 2
Institution
Greenfield Institute for Rare Disease
Principal investigators
A. Petrov, J. Mwangi
Targets
DMD
Pathways
Dystrophin replacement
Trial registry
NCT04335942

Intake & funding

Applications

None recorded.

Funding events
  • trancheUSD1,500,000Series B2025-02-01

Timeline

state through time · newest first
  1. Q2 2025Series B funded
    Milestones
    • ·Potency assay comparability achieved
    Accomplishments
    • ·Manufacturing yield improved 2x
    Challenges
    • ·Pre-existing AAV immunity excludes a third of candidates
    Next steps
    • ·Interim functional analysis
    • ·Engage FDA on surrogate
    Risk themes:Immunogenicity exclusionCost of goods
  2. Q1 2025Series B funded
    Milestones
    • ·Phase 2 functional cohort enrolled
    Accomplishments
    • ·Microdystrophin expression confirmed on biopsy
    Challenges
    • ·Functional benefit not yet separated from standard of care
    Next steps
    • ·Collect 12-month NSAA
    • ·Optimize potency assay
    Risk themes:High AAV dose / CMC scale-upFunctional translation unproven

Scientific assessment

1 claims
  • Supporting EvidenceModerate

    Systemic AAV microdystrophin raises dystrophin expression on biopsy; functional translation across age bands remains the open question.

    trialNCT04335942

Translational assessment

1 claims
  • ManufacturingLimited

    High systemic AAV doses constrain CMC scale-up and cost of goods; potency-assay comparability is a gating activity.

    internalcmc-2024

Regulatory assessment

1 claims
  • Accelerated ApprovalModerate

    Microdystrophin expression has been accepted as a surrogate reasonably likely to predict benefit, supporting accelerated approval.

    regulatoryaa-dmd

Commercial assessment

0 claims

No evidence linked yet.

Execution assessment

0 claims

No evidence linked yet.

Structured reviews

1 reviews
Mixed· medium confIndustryGene therapy advisor2025-02-22
Strengths

Surrogate accepted; expression confirmed.

Weaknesses

Functional translation unproven; CMC and immunogenicity hurdles.

Improvement areas

Demonstrate functional separation from standard of care.

Internal rubric input (reviewer scoring — not a success probability)
Scientific validity
Translational readiness
Regulatory pathway
Commercial potential
Execution strength

Outcome

  • Clinical entry
    Phase 2 functional cohort enrolled.2025-01-05

AI brief

flag off · defaultPhase 7

Runtime AI features are flag-gated and disabled by default. Set SIGNAL_LLM_ENABLED=1 (plus a provider key) to enable a grounded, source-cited brief generated from this asset's structured records — with forbidden-phrase and grounding validators enforcing no probability-of-success or buy/sell language.

Evidence tiers and reviewer rubric scores are internal, qualitative inputs — [signal.] surfaces never show a numeric probability of success or buy/sell language.